Dr. Xiaoxiang Chen 陈小祥
Chief Physician, Associate Professor
Department of Gynecologic Oncology Surgery, Jiangsu Cancer Hospital, Nanjing
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Surgical treatment and chemotherapy for gynecologic malignancies, with a focus on cervical, uterine, and ovarian tumors.
Dr. Chen holds a PhD from Nanjing University and completed postdoctoral work at Southeast University. With 20 years in gynecologic oncology, Dr. Chen served as a visiting associate professor at Taipei Veterans General Hospital and the US M.D. Anderson Cancer Center. Dr. Chen has published over 10 SCI papers, co-edited one oncology monograph, and received a Jiangsu Science and Technology Progress Award.
Professional roles
- Member, National Youth Committee of the Gynecologic Oncology Professional Committee, China Anti-Cancer Association
- Academic Editor, Journal of Medical Postgraduates
- Academic Editor, Gynecologic Oncology Research and Practice
- Reviewer, PLOS ONE, Gynecologic Oncology, International Journal of Gynecologic Cancer, Chemotherapy
Name order: in Chinese the family name comes first (Chen Xiaoxiang). Papers usually list the name as Xiaoxiang Chen or Chen X.
Selected publications
42 papers on PubMed matched by name and affiliation; 19 as first or senior author since 2016. Most recent first- or senior-author papers:
- Front Cell Infect Microbiol, 2026 (senior author): Investigating the diversity of intratumoral microbiota in high-grade serous ovarian cancer with varying platinum sensitivity. PubMed 42328173
- Cancer Med, 2026 (senior author): Efficacy and Safety of Multivisceral Resection for Ovarian Cancer: A Comparative Study of Gynecologic Oncologists and Multidisciplinary Surgeons. PubMed 41942413
- BMC Surg, 2025 (senior author): Infective endocarditis after splenectomy for ovarian cancer: a case report. PubMed 41299394
- Eur J Obstet Gynecol Reprod Biol, 2025 (senior author): Niraparib combined with anlotinib after PARPi resistance in ovarian cancer: A single-center retrospective study from China. PubMed 40967072
- Genes Dis, 2025 (senior author): Multi-omics approach reveals gene co-alterations and survival benefit in ovarian cancer patients under platinum-based adjuvant therapy. PubMed 40687614
- J Ovarian Res, 2024 (senior author): Genomic alteration discordance in the paired primary-recurrent ovarian cancers: based on the comprehensive genomic profiling (CGP) analysis. PubMed 38937827
- Reprod Sci, 2023 (senior author): Platinum Resistance After PARPi Resistance in a gBRCAmt Recurrent Ovarian Cancer Patient: a Case Report. PubMed 35943701
- Front Oncol, 2021 (senior author): Homologous Recombination Deficiency Associated With Response to Poly (ADP-ribose) Polymerase Inhibitors in Ovarian Cancer Patients: The First Real-World Evidence From China. PubMed 35070965
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion